ATE71303T1 - Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. - Google Patents

Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.

Info

Publication number: ATE71303T1
Authority: AT; Austria
Prior art keywords: immunogenic; preparation; pharmaceutical composition; composition containing; detergent
Prior art date: 1986-01-14

Application number

AT87200035T

Other languages

English (en)

Inventor

Vries Petra De

Wezel Antonius Ludovicus Van

Eduard Coen Beuvery

Original Assignee

Nederlanden Staat

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-01-14

Filing date

1987-01-13

Publication date

1992-01-15

1987-01-13 Application filed by Nederlanden Staat filed Critical Nederlanden Staat

1992-01-15 Application granted granted Critical

1992-01-15 Publication of ATE71303T1 publication Critical patent/ATE71303T1/de

Links

230000001900 immune effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000002163 immunogen Effects 0.000 abstract 4
229930182558 Sterol Natural products 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
230000000890 antigenic effect Effects 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000003599 detergent Substances 0.000 abstract 2
229930182470 glycoside Natural products 0.000 abstract 2
150000002338 glycosides Chemical class 0.000 abstract 2
239000000693 micelle Substances 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
150000003432 sterols Chemical class 0.000 abstract 2
235000003702 sterols Nutrition 0.000 abstract 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 abstract 1
238000004220 aggregation Methods 0.000 abstract 1
230000002776 aggregation Effects 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
229930182490 saponin Natural products 0.000 abstract 1
150000007949 saponins Chemical class 0.000 abstract 1
235000017709 saponins Nutrition 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Dispersion Chemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT87200035T 1986-01-14 1987-01-13 Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. ATE71303T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8600066		1986-01-14
EP87200035A EP0231039B1 (de)	1986-01-14	1987-01-13	Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung

Publications (1)

Publication Number	Publication Date
ATE71303T1 true ATE71303T1 (de)	1992-01-15

Family

ID=19847414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87200035T ATE71303T1 (de)	1986-01-14	1987-01-13	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.

Country Status (8)

Country	Link
US (1)	US4900549A (de)
EP (1)	EP0231039B1 (de)
JP (2)	JP2502558B2 (de)
AT (1)	ATE71303T1 (de)
CA (1)	CA1279012C (de)
DE (1)	DE3775783D1 (de)
DK (1)	DK166762B1 (de)
ES (1)	ES2039229T3 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) *	1986-01-14	1992-01-15	Nederlanden Staat	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5583112A (en) *	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
DE3863908D1 (de) *	1987-11-27	1991-08-29	Akzo Nv	Stabilisierung von antikoerpern.
US6291228B1 (en)	1988-08-03	2001-09-18	Vericore Limited	Vaccine
NZ230747A (en) *	1988-09-30	1992-05-26	Bror Morein	Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8919819D0 (en) *	1989-09-01	1989-10-18	Coopers Animal Health	Complexes having adjuvant activity
US4981684A (en) *	1989-10-24	1991-01-01	Coopers Animal Health Limited	Formation of adjuvant complexes
US5178860A (en) *	1989-09-01	1993-01-12	Coopers Animal Health Limited	Adjuvant complexes and vaccine made therefrom
US5443832A (en) *	1990-04-16	1995-08-22	Institut Swisse De Recherches Experimentales Sur Le Cancer	Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
NL9002314A (nl) *	1990-10-23	1992-05-18	Nederlanden Staat	Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) *	1991-05-31	1995-11-13	British Tech Group	Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
WO1993020802A1 (en) *	1992-04-09	1993-10-28	Northwestern University	Acoustically reflective liposomes and methods to make and use the same
DE4220653A1 (de) *	1992-06-26	1994-01-13	Boehringer Mannheim Gmbh	Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
ES2145132T3 (es) *	1993-02-26	2000-07-01	Fountain Pharm Inc	Sistema de suministro de vacunas y solucion precursora estable en almacenamiento para la encapsulacion a distancia de ingredientes activos.
AUPM500494A0 (en) *	1994-04-12	1994-05-05	Minister For Agriculture & Rural Affairs For The State Of New South Wales, The	Composition for use in increasing mucosal immunity
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
GB9618119D0 (en)	1996-08-30	1996-10-09	Univ Southampton	Adjuvants for use in vaccines
US6455323B1 (en)	1997-07-03	2002-09-24	Pharmacia & Upjohn Company	Anti-bacterial methods and materials
US20070059327A2 (en) *	1998-01-15	2007-03-15	Wyeth	Streptococcus equi compositions and methods of use
GB2348203B (en)	1998-11-04	2002-06-19	Imp College Innovations Ltd	Solube beta-forms of prion proteins, methods of preparation and use
AUPP807399A0 (en)	1999-01-08	1999-02-04	Csl Limited	Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
HK1045856A1 (zh)	1999-04-09	2002-12-13	法玛西雅厄普约翰美国公司	抗细菌疫苗组合物
US6790950B2 (en)	1999-04-09	2004-09-14	Pharmacia & Upjohn Company	Anti-bacterial vaccine compositions
DE60112413T2 (de)	2000-03-17	2006-06-01	Pharmacia & Upjohn Co. Llc, Kalamazoo	Ssa inaktivierte salmonella impfstoffe
WO2001077365A2 (en)	2000-04-06	2001-10-18	Pharmacia & Upjohn Company	Antimicrobial methods and materials
US7323174B1 (en)	2000-06-12	2008-01-29	Arizona Board Of Regents On Behalf Of The University Of Arizona	Modulation of immune response and methods based thereon
CU23002A1 (es) *	2000-12-01	2004-11-18	Ct Ingenieria Genetica Biotech	Método de obtención de agregados antigénicos y su uso en formulaciones
CA2327950A1 (en) *	2000-12-08	2002-06-08	Groupe Minutia Inc.	Grain refining agent for cast aluminum or magnesium products
US7713942B2 (en) *	2001-04-04	2010-05-11	Nordic Vaccine Technology A/S	Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0112126D0 (en)	2001-05-18	2001-07-11	Allergene Inc	Composition
IL145926A0 (en)	2001-10-15	2002-07-25	Mor Research Applic Ltd	Peptide epitopes of mimotopes useful in immunomodulation
US6861410B1 (en)	2002-03-21	2005-03-01	Chiron Corporation	Immunological adjuvant compositions
SE0202110D0 (sv) *	2002-07-05	2002-07-05	Isconova Ab	Iscom preparation and use thereof
AU2003296592A1 (en)	2002-11-20	2004-06-15	Crucell Holland B.V.	Antigen-complexes
US7491395B2 (en)	2002-11-20	2009-02-17	Bestewil Holding B.V.	Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US20060233863A1 (en)	2003-02-10	2006-10-19	Enzymotec Ltd.	Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
IL155136A0 (en) *	2003-02-10	2003-10-31	Enzymotec Ltd	A composition for reducing blood cholesterol and triglycerides
EP1447080A1 (de) *	2003-02-13	2004-08-18	Bestewil Holding B.V.	Methode zur Herstellung von Virosomen-artigen Partikeln
SE0300795D0 (sv)	2003-03-24	2003-03-24	Isconova Ab	Composition comprising iscom particles and live micro-organisms
AR056245A1 (es)	2003-06-19	2007-10-03	Bestewil Holding Bv	Membranas virales reconstituidas funcionales que contienen un coadyuvante
GB0315323D0 (en)	2003-07-01	2003-08-06	Royal Veterinary College	Vaccine composition
US9023366B2 (en)	2003-07-01	2015-05-05	The Royal Veterinary College	Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
SE0301998D0 (sv) *	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
US20060287263A1 (en)	2004-07-18	2006-12-21	Csl Limited	Methods and compositions for inducing antigen-specific immune responses
AU2005270825B2 (en) *	2004-08-09	2011-07-07	Enzymotec Ltd.	Food products for diabetics
AU2005270831B2 (en)	2004-08-10	2011-08-25	Enzymotec Ltd.	Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
US8007806B2 (en) *	2005-01-20	2011-08-30	Isconova Ab	Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
WO2006133879A2 (en)	2005-06-16	2006-12-21	Universiteit Gent	Vaccines for immunization against helicobacter
EP1896500A4 (de) *	2005-06-28	2010-08-11	Yeda Res & Dev	Gliomedin, fragmente davon und verfahren zu ihrer anwendung
ES2357679T3 (es)	2005-07-28	2011-04-28	Pfizer Products Inc.	VACUNA CONTRA CALICIVIRUS FELINO (FCV) QUE COMPRENDE UNA PROTEINA DE CAPSIDA DE UN FCV O UNA PROTEINA DE LA CAPSIDA DE UN FCV AISLADA QUE COMPRENDE UNA SECUENCIA PROTEICA SEC ID Nº: 13 O SECUENCIAS PROTEICAS CON, AL MENOS, 95% DE IDENTIDAD CON ELLA.
EP1764369A1 (de)	2005-09-16	2007-03-21	Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH	Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
ME00485B (me)	2005-10-07	2011-10-10	Zoetis Services Llc	VAKCINE l METODE LIJEČENJA INFLUENCE KOD CANINA
CA2674026C (en)	2006-12-27	2018-08-21	Pfizer Products Inc.	Methods of vaccine administration
WO2008142693A2 (en) *	2007-05-22	2008-11-27	Yeda Research And Development Co. Ltd.	Regulation of myelination by nectin-like (necl) molecules
JP2010038051A (ja)	2008-08-06	2010-02-18	Denso Corp	車載動力発生装置のトルク制御装置
AU2011252844B2 (en)	2010-05-14	2014-07-03	Baxalta GmbH	Chimeric OspA genes, proteins, and methods of use thereof
SG186783A1 (en) *	2010-06-24	2013-02-28	Genentech Inc	Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
WO2012010291A1 (en)	2010-07-21	2012-01-26	Athera Biotechnologies Ab	Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en)	2010-07-21	2012-01-26	Athera Biotechnologies Ab	Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012059593A1 (en)	2010-11-05	2012-05-10	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Vaccines for preventing meningococcal infections
EP2462950A1 (de)	2010-12-08	2012-06-13	Neovacs	Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
AU2011340477A1 (en)	2010-12-08	2013-06-20	Neovacs	Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
WO2012131099A1 (en)	2011-03-31	2012-10-04	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
WO2012136739A1 (en)	2011-04-07	2012-10-11	Neovacs	Method for treating ifnalpha related conditions
EP2508197A1 (de)	2011-04-07	2012-10-10	Neovacs	Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen
DK2750683T4 (da)	2011-10-03	2021-04-12	Croda Int Plc	Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
GB201200259D0 (en)	2012-01-09	2012-02-22	Ohlin Per M	Novel therapies
AU2013293448A1 (en)	2012-07-27	2015-02-05	Baxalta GmbH	Compositions comprising chimeric OspA molecules and methods of use thereof
EP2949339A1 (de)	2014-05-29	2015-12-02	Ospedale San Raffaele S.r.l.	Agonisten von CD1c-abhängigen T Zellen und Verwendungen davon
EP3207055A1 (de)	2014-10-15	2017-08-23	Xenothera	Zusammensetzung mit verminderter immunogenität
CA2996007A1 (en)	2015-09-03	2017-03-09	Novavax, Inc.	Vaccine compositions having improved stability and immunogenicity
JP7317796B2 (ja)	2017-07-24	2023-07-31	ノババックス，インコーポレイテッド	呼吸器疾患を治療するための方法および組成物
CN120227451A (zh)	2018-03-19	2025-07-01	诺瓦瓦克斯股份有限公司	多价流感纳米颗粒疫苗
US10953089B1 (en)	2020-01-27	2021-03-23	Novavax, Inc.	Coronavirus vaccine formulations
EP3922255A1 (de)	2020-06-10	2021-12-15	Prokarium Limited	Krebstherapie
EP4124342A1 (de)	2021-07-28	2023-02-01	Prokarium Limited	Krebstherapie mit lebenden attenuierten bakterien
GB2622559A (en)	2022-05-10	2024-03-27	Johan Frostegaard	Compositions, methods and uses
GB202215134D0 (en)	2022-10-13	2022-11-30	Prokarium Ltd	Composition
GB202215576D0 (en)	2022-10-21	2022-12-07	Prokarium Ltd	Circuit
WO2025068413A1 (en)	2023-09-28	2025-04-03	Prokarium Limited	Interleukin 18 variants
AU2024353556A1 (en)	2023-09-28	2026-04-02	Prokarium Limited	Interleukin 15 variant
WO2025109155A1 (en)	2023-11-24	2025-05-30	Prokarium Limited	Interleukin variant
KR20250155284A (ko) *	2024-04-23	2025-10-30	(주)아모레퍼시픽	미셀을 이용한 유효성분의 봉입 및 안정성 개선 방법
GB202405780D0 (en)	2024-04-24	2024-06-05	Prokarium Ltd	Vacuole escape
WO2025224251A1 (en)	2024-04-24	2025-10-30	Prokarium Limited	Modified microorganisms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
US4196191A (en) *	1975-09-29	1980-04-01	Burroughs Wellcome Co.	Biological preparations
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
AU534679B2 (en) *	1979-03-15	1984-02-09	Commonwealth Scientific And Industrial Research Organisation	Steroid immunogens
DE3068743D1 (en) *	1980-01-16	1984-08-30	Weder Hans G	Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4439199A (en) *	1980-02-19	1984-03-27	Alza Corporation	Method for administering immunopotentiator
DE3014189A1 (de) *	1980-04-14	1981-10-15	Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg	Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4386066A (en) *	1981-08-20	1983-05-31	Merck & Co., Inc.	Immunogenic complex from N. gonorrhoeae
SE8205892D0 (sv) *	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0142192A1 (de) *	1983-10-22	1985-05-22	Akzo N.V.	Herstellung von Immunogenen bestehend aus an Glykosid enthaltenden Trägern gebundenen antigenen Determinanten
SE8405493D0 (sv) *	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) *	1986-01-14	1992-01-15	Nederlanden Staat	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806350A (en) *	1986-04-18	1989-02-21	Norden Laboratories, Inc.	Vaccine formulation

1987
- 1987-01-13 AT AT87200035T patent/ATE71303T1/de not_active IP Right Cessation
- 1987-01-13 ES ES198787200035T patent/ES2039229T3/es not_active Expired - Lifetime
- 1987-01-13 DK DK015087A patent/DK166762B1/da not_active IP Right Cessation
- 1987-01-13 DE DE8787200035T patent/DE3775783D1/de not_active Expired - Lifetime
- 1987-01-13 EP EP87200035A patent/EP0231039B1/de not_active Expired - Lifetime
- 1987-01-14 CA CA000527289A patent/CA1279012C/en not_active Expired - Lifetime
- 1987-01-14 JP JP62007384A patent/JP2502558B2/ja not_active Expired - Lifetime
- 1987-01-14 US US07/003,070 patent/US4900549A/en not_active Expired - Lifetime
1995
- 1995-11-28 JP JP7309056A patent/JP2703528B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2703528B2 (ja)	1998-01-26
JPH08208513A (ja)	1996-08-13
DK166762B1 (da)	1993-07-12
DK15087A (da)	1987-07-15
CA1279012C (en)	1991-01-15
DK15087D0 (da)	1987-01-13
EP0231039B1 (de)	1992-01-08
DE3775783D1 (de)	1992-02-20
ES2039229T3 (es)	1993-09-16
JPS632933A (ja)	1988-01-07
US4900549A (en)	1990-02-13
JP2502558B2 (ja)	1996-05-29
EP0231039A1 (de)	1987-08-05

Legal Events

Date	Code	Title	Description
1992-09-15	UEP	Publication of translation of european patent specification
2007-04-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
ATE71303T1 (de)	1992-01-15	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
DE68921389T2 (de)	1995-06-29	Influenzaimpfstoff und Adjuvanten.
DE69010574T2 (de)	1994-10-27	Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält.
KR940001373B1 (ko)	1994-02-21	인플루엔자 백신의 제조방법
CA2086831C (en)	1999-03-16	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU632067B2 (en)	1992-12-17	Matrix with immunomodulating activity
DE69131709T2 (de)	2000-05-25	Liposomen enthaltende impfstoffzusammensetzungen
ATE71834T1 (de)	1992-02-15	Liposomzubereitung und ihre herstellung.
JP2002522397A (ja)	2002-07-23	他の界面活性剤を含有しない、ステロールとサポニンから成るｉｓｃｏｍを含むワクチン
DK0524968T3 (da)	1995-07-31	Heterovesikulære lipidvesikler
RO119068B1 (ro)	2004-03-30	Compoziţie de vaccin conţinând o saponină şi un sterol
US4148876A (en)	1979-04-10	Biological preparations
ZA834998B (en)	1984-04-25	Liquid active ingredient concentrates for preparation of microemulsions
DE69026380D1 (de)	1996-05-09	Zielliposomen und verfahren zur kupplung von liposomen-proteinen
KR950700083A (ko)	1995-01-16	경구용 백신(oral vaccine)
GB1564500A (en)	1980-04-10	Biological preparations
DE69505236T2 (de)	1999-05-20	Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel
KR0173365B1 (ko)	1999-02-01	C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
Freitas et al.	1998	The Use of Liposomes as Snake Venom Vehicles. Application in Protective Immunization
DE69710476T2 (de)	2002-10-10	Alkaloidglykoside zur verwendung als arzneimittel
KR0178422B1 (ko)	1999-03-20	한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
KR0173366B1 (ko)	1999-02-01	B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀
DK302987A (da)	1987-08-14	Fremgangsmaade til fremstilling af et immunogent kompleks
JP2004161781A (ja)	2004-06-10	経口ワクチン
JPS63275522A (ja)	1988-11-14	人工赤血球及びその製造方法